Video

Dr. El-Khoueiry Discusses Recent Combination Data in HCC

Anthony El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses recent combination data in hepatocellular carcinoma.

Anthony El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses recent combination data in hepatocellular carcinoma (HCC).

There was a lot of discussion surrounding early trials in HCC during the 2018 International Liver Cancer Association Annual Conference, says El-Khoueiry. This includes some trials looking at combination therapy. Most of these trials are looking at anti—PD-1/PD-L1 agents with either tyrosine kinase inhibitors (TKIs) such as sorafenib (Nexavar) and lenvatinib (Lenvima), or with anti-VEGF agents.

One of the trials presented at the conference was the combination of atezolizumab (Tecentriq) with bevacizumab (Avastin). Although it showed a response rate of 60%, it was in a small number of patients, so El-Khoueiry says that this should be interpreted with caution. Further data is awaited. Nonetheless, there is excitement for the possibility for combinations of anti—PD-1/PD-L1 agents with anti-VEGF or TKIs in general, El-Khoueiry concludes.

Related Videos
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO